Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr 26;8(Suppl 1):27-35.
doi: 10.4137/BiC.s34414. eCollection 2016.

Biomarkers and Targeted Therapy in Pancreatic Cancer

Fataneh Karandish  1 , Sanku Mallik  1
Affiliations
Review

Biomarkers and Targeted Therapy in Pancreatic Cancer

Fataneh Karandish et al. Biomark Cancer. .

Abstract

Pancreatic ductal adenocarcinoma (PDAC) constitutes 90% of pancreatic cancers. PDAC is a complex and devastating disease with only 1%-3% survival rate in five years after the second stage. Treatment of PDAC is complicated due to the tumor microenvironment, changing cell behaviors to the mesenchymal type, altered drug delivery, and drug resistance. Considering that pancreatic cancer shows early invasion and metastasis, critical research is needed to explore different aspects of the disease, such as elaboration of biomarkers, specific signaling pathways, and gene aberration. In this review, we highlight the biomarkers, the fundamental signaling pathways, and their importance in targeted drug delivery for pancreatic cancers.

Keywords: EGFR; EMT; KRAS; MMPs; MYC; NF-κB; PAF; PIM; RAGE; mTOR; miRNA; pancreatic cancer; pancreatic cancer stem cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Signaling pathways stimulated by the activation of EGFR kinase.
Figure 2
Figure 2
RAS protein regulation through the GTP/GDP cycle.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lindberg JM, Newhook TE, Adair SJ, et al. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer. Neoplasia. 2014;16(7):562–571. - PMC - PubMed
    1. American Cancer Society, Pancreatic Cancer (2015) 2015. http://www.cancer.org/cancer/pancreaticcancer/index.
    1. Jung H-Y, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial–mesenchymal transition in metastasis. Clin Cancer Res. 2015;21(5):962–968. - PMC - PubMed
    1. Collisson EA, Sadanndam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17(4):500–503. - PMC - PubMed
    1. Morse DL, Balagurunathan Y, Hostetter G, et al. Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol. 2010;80(5):748–754. - PMC - PubMed